Impact of GVHD on outcomes in the multivariate analyses
| . | HR (95% CI) . | P value . |
|---|---|---|
| NRM | ||
| No classic | 1 | Ref |
| Classic | 2.53 (2.13-3.02) | < .001 |
| No classic/late | 1 | Ref |
| Late | 4.37 (3.03-6.30) | < .001 |
| Relapse | ||
| No classic | 1 | Ref |
| Classic | 0.77 (0.66-0.90) | .001 |
| No classic/late | 1 | Ref |
| Late | 1.26 (0.86-1.86) | .236 |
| OS | ||
| No classic | 1 | Ref |
| Classic | 1.50 (1.32-1.70) | < .001 |
| No classic/late | 1 | Ref |
| Late | 2.29 (1.72-3.04) | < .001 |
| . | HR (95% CI) . | P value . |
|---|---|---|
| NRM | ||
| No classic | 1 | Ref |
| Classic | 2.53 (2.13-3.02) | < .001 |
| No classic/late | 1 | Ref |
| Late | 4.37 (3.03-6.30) | < .001 |
| Relapse | ||
| No classic | 1 | Ref |
| Classic | 0.77 (0.66-0.90) | .001 |
| No classic/late | 1 | Ref |
| Late | 1.26 (0.86-1.86) | .236 |
| OS | ||
| No classic | 1 | Ref |
| Classic | 1.50 (1.32-1.70) | < .001 |
| No classic/late | 1 | Ref |
| Late | 2.29 (1.72-3.04) | < .001 |
GVHD was treated as a time-dependent covariate. All models were adjusted for recipient’s age, sex mismatch, primary disease, disease risk, donor type, GVHD prophylaxis, HCT-CI, in vivo T-cell depletion, donor source, conditioning, and the year of HCT. In late acute GVHD analysis, CNI discontinuation by day 100 was also included. GVHD was treated as a time-dependent covariate. The number of events for NRM, relapse, and OS was 573, 806, and 1086, respectively.